Company intelligence
nference
Making biomedical knowledge computable
Biotechnology Research
Cambridge, US
313 employees
Founded 2013
6 public signals
About nference
nference leverages the top academic minds, world-class researchers, and real-time access to multimodal, patient-level data to accelerate drug development innovation, generate evidence, and improve clinical trial processes. nSights, our flagship software platform, delivers the most comprehensive biological and clinical insights into patient care.
Verified activity
Signals from nference
6 published signals
Research & Knowledge
nference published a 652-patient study on its patients turning to purported gray-market retatrutide, highlighting the gap between clinical-trial promise and real-world experience.
Reported by Venky Soundararajan, Ph.D.
Research & Knowledge
nference published a peer-reviewed study in Biology Methods and Protocols highlighting routine care signals from sustained initiation-dose GLP-1 therapy in a federated real-world dataset of de-identified U.S. patients.
Reported by Venky Soundararajan, Ph.D.
Partnerships
nference announced that Rush University Medical Center is the first Illinois-based academic medical center to partner with nference.
Reported by nference
Partnerships
nference announced a long-term strategic partnership with Rush University System for Health to advance AI-enabled clinical research and patient care.
Reported by nference
Research & Knowledge
nference published a peer-reviewed observational study exploring whether every patient needs the highest tolerated GLP-1 dose, examining de-identified healthcare outcomes from patients on semaglutide or tirzepatide.
Reported by Venky Soundararajan, Ph.D.
Research & Knowledge
nference published a study in the peer-reviewed Oxford University Press journal Biology Methods & Protocols covering the nference study on the dosing and efficacy of semaglutide and tirzepatide.
Reported by Venky Soundararajan, Ph.D.